Ensuring patient access to cell and gene therapies - The case for an innovative payment model

The BioIndustry Association (BIA) has launched Ensuring patient access to cell and gene therapies: The case for an innovative payment model. The report, which has been produced with the support of the BIA’s Cell and Gene Therapy Advisory Committee, explores the potential benefits of cell and gene therapies for patients, the challenges they face in the current system and some of the solutions being explored in other countries. 

The BIA would like to thank the following member companies which have financially supported this report: Astellas, Autolus, Gilead Sciences, Novartis and Sarepta Therapeutics.